glp-1 agonists

It’s no secret that America is facing an obesity crisis. But is there hope on the horizon? The new wave of weight-loss medications — Wegovy and Zepbound  — certainly seem to be game changers. Whereas previous options helped people lose only around 5% of their weight, these new medications can lead to up to 22% weight loss. But you’re not alone if you have questions. In this episode, we discuss everything we know (and don’t yet know) about the new class of weight-loss medications.

Expert: Dr. Garth Davis, Weight Loss Surgeon

Interviewer: Zach Moore

Notable topics covered: 

• How weight-loss medication compares to bariatric surgery
• Weight-loss medications vs. supplements
• The many reasons why losing weight often isn’t as simple as diet and exercise 
• How the new wave of weight-loss medications work
• All about GLP-1 agonists, including why achieving “the GLP-1 effect” promotes weight loss
• Who should consider taking these medications? And are they covered by insurance? 
• Just one tool to get weight off: why diet and exercise still matter
• Will you need to stay on this medication forever?
• How these medications also benefit heart health, type 2 diabetes management and more
• The potential side effects of weight-loss medications

If you enjoy these kinds of conversations, be sure to subscribe. And for more topics like this, visit our blog at houstonmethodist.org/blog.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/

This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization as a means of providing foundational context for learners. Expert faculty will then lead attendees on an immersive, deep dive through the established paradigm and the preponderance of emerging data for novel weight-loss therapeutics, most notably the GLP-1 agonists and the GLP-1/GIP agonists. The session will conclude with a case-based segment, in which attendees will get to apply the principles they have learned to real-world clinical scenarios, address practical weight-loss challenges, and highlight the instrumental role of the primary care physician as a gatekeeper for the obesity management team.  Request credit here: https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/

Supported through an independent educational grant from Lilly.

Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about medications for type 2 diabetes.

Listen in as they debate whether metformin should still be first-line for all patients with type 2 diabetes...and discuss the role of GLP-1 agonists and SGLT2 inhibitors in these patients.

You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:

• Reid B. Blackwelder, MD, FAAFP, Associate Dean of Graduate and Continuing Medical Education at East Tennessee State University
• Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University
• Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science University

For the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.

Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.

If you’re not yet a Pharmacist’s Letter or Prescriber Insights subscriber, find out more about our product offerings at trchealthcare.com.

Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP). With the approval, Eli Lilly will be giving Novo Nordisk’s blockbuster diabetes injection Ozempic some tough competition. Hear about the projected sales of Mounjaro, data from studies that led to its approval and its impact from a patient perspective.

Ayesha also talked about the current monkeypox outbreak as clusters of cases continue to be reported in countries in Europe and North America. The US recently reported its first case of monkeypox, and all cases so far are linked to international travel. Learn more about monkeypox and how health authorities are asking people not to panic as most cases are mild and treatable. Also hear about how Britain is offering the smallpox vaccine to healthcare workers to help prevent infection from the monkeypox virus.

Read the full articles here: 

Mounjaro (tirzepatide), Eli Lilly’s Highly Awaited Type 2 Diabetes Injection Gets FDA Nod

Monkeypox Case Reported in the US as Virus Spreads Across Europe and North America

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

NASH-TAG Co-director Michael Charlton and Ian Rowe join Roger, Louise and Donna to review the morning that Michael himself identified as one of two highlight sessions of NASH-TAG 2021.

The Saturday morning session of NASH-TAG 2021 envisions a world of clinical trials without biopsies, considers implications of enrolling co-morbid and other challenging patients, ands winds up with a debate about the role of diabetes drugs in the future of NASH therapies. After the session, join SurfingNASH to sort out how what the data means, how the pieces fit together and what questions will require more exploration. If you send us any questions emerging from Session #3 or the podcast, we will review them in later NASH-TAG episodes and try to get feedback from those at the meeting.

The panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success.

Louise Campbell and Roger Green discuss issues and challenges in educating diabetic patients about NAFLD and NASH. Louise discusses how the rising amount of mortality tied to liver cancer should create a new urgency to broaden focus about the role the liver plays in metabolic health. Roger raises the role that reference labs like Quest and LabCorp have played in driving awareness of underappreciated diseases. The group has several ideas and avenues to explore. Listeners take heed...we have much to figure out and do.

Wayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and the liver issues related to diabetes.

Patient, patient advocate and Fatty Liver Foundation Wayne Eskridge considers ways that diabetic patients might respond to the joint ideas that they have fatty liver issues and that some diabetes drugs might treat them. He considers issues of information overload and education and the pivotal role physician advocacy plays in driving that education. The other panelists discuss the need for multiple specialties to collaborate in educating patients and providing a more holistic view of how metabolic diseases interact to damage patient health.

Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH.

The group considers scientific issues surrounding the newer diabetes drugs. First, Jörn Schattenberg presented mode-of-action and research data on the two classes of drugs. After this, Wayne Eskridge asked questions from the patient perspective, Louise Campbell explores issues from a holistic perspective and Roger Green raised data points and concepts that arose in earlier episodes of the podcast.